Dietary advanced glycated end-products and medicines influence the expression ofSIRT1andDDOSTin peripheral mononuclear cells from long-term type 1 diabetes patients

Autor: Ana Mercedes Cavaleiro, Sharon Nina Admoni, Ricardo Vessoni Perez, Marisa Passarelli, Daniele Pereira Santos-Bezerra, Márcia Silva Queiroz, Karina Thieme, Daniel Giannella-Neto, Ubiratan Fabres Machado, Maria Lúcia Corrêa-Giannella, Maria Heloíza Shimizu, Maria Beatriz Monteiro, Cleide Guimarães Machado, Adriana Machado-Lima
Rok vydání: 2017
Předmět:
Adult
Glycation End Products
Advanced
Male
medicine.medical_specialty
Endocrinology
Diabetes and Metabolism
Receptor for Advanced Glycation End Products
030209 endocrinology & metabolism
030204 cardiovascular system & hematology
Peripheral blood mononuclear cell
Gene Expression Regulation
Enzymologic
RAGE (receptor)
Angiotensin Receptor Antagonists
03 medical and health sciences
0302 clinical medicine
Sirtuin 1
Interquartile range
Glycation
Internal medicine
Diabetes mellitus
Internal Medicine
medicine
Humans
Diabetic Nephropathies
RNA
Messenger
ANGIOTENSINAS
Receptor
Type 1 diabetes
business.industry
Membrane Proteins
medicine.disease
Diet
Oxidative Stress
Cross-Sectional Studies
Diabetes Mellitus
Type 1
Real-time polymerase chain reaction
Endocrinology
Hexosyltransferases
Case-Control Studies
Leukocytes
Mononuclear
Female
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiology and Cardiovascular Medicine
business
Biomarkers
Diabetic Angiopathies
Zdroj: Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
ISSN: 1752-8984
1479-1641
Popis: Quantitative polymerase chain reaction was employed to quantify expression of two genes coding for advanced glycation end-product receptors [RAGE ( AGER) and AGER1 ( DDOST)] and of the gene coding the deacetylase SIRT1 ( SIRT1) in peripheral blood mononuclear cells from type 1 diabetes patients without [Group A, n = 35; 28.5 (24-39) years old; median (interquartile interval)] or with at least one microvascular complication [Group B, n = 117; 34.5 (30-42) years old]; 31 healthy controls were also included. In a subgroup of 48 patients, daily advanced glycation end-products intake before blood collection was assessed. Lower expression of DDOST was found in patients than in controls after adjustment for sex, age, use of statins, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Higher expressions of AGER, DDOST and SIRT1 were observed in Group A. Stratifying by complications, AGER and DDOST expressions were higher in those without retinopathy and without diabetic kidney disease, respectively, compared to patients with these complications. Patients using statins or angiotensin receptor blockers presented higher expression of DDOST. Expression of SIRT1 was higher in patients consuming ≥12,872 KU daily of advanced glycation end-products. Although AGER, DDOST and SIRT1 are differently expressed in peripheral blood mononuclear cells from type 1 diabetes patients with and without microvascular complications, they are also influenced by dietary advanced glycation end-products and by statins and angiotensin receptor blockers.
Databáze: OpenAIRE
Externí odkaz: